May 20, 2014 – Dr. L'Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research ("Assises Nationales de la Recherche en Biomatériaux"; Autrans, France).
May 5, 2014 - Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco.  Program details can be found here.
April 27, 2014 – Dr. L'Heureux to present recent results regarding the use of "Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications" at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 - Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L'Heureux to speak at the INSERM Workshop #226 "3D cell culture bridges the gap between cell culture and live tissue" (Bordeaux, France).
March 14, 2014 - Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School  (Shanghai, China). 
October 7, 2013 - Results from the "First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access" are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 - Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report.  In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies.  See the full length manuscript in Regenerative Medicine here.
 
PIPELINE

Cytograft maintains a focused product portfolio targeted at cell-based solutions to cardiovascular disease. The company's lead product has shown promising results in phase I/II clinical trials as reported in the Lancet.

Our follow-on products include the LifeGuard™ patch and the LifeJacket™ stent-graft. These products take advantage of Cytograft's expertise in Tissue Engineering by Self-Assembly (TESA) and biological based treatments. These follow-on technologies range from discovery stage to advanced pre-clinical research to support FIM (first in man).

The company is also developing a line of surgical devices to support percutaneous bypass and other minimally invasive surgical approaches.

link to tebv link to covered stent link to patch link to percutaneous bypass link to valve

Gant Chart - Development Stage